InsidersTradesSigma
Track the 바이오노트 share price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 바이오노트 has published 2 public disclosures. Market capitalisation: €452.4bn. The latest transaction was reported on 21 April 2026 (Purchase). Among the most active insiders: 조영식. The full history is openly available.
2
Insider Decl.
n/a
Thresholds
€206,824
2 ops.
Buy Volume
n/a
n/a
Sell Volume
4Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,135 of 29,056 companies
31.0
score / 100
Value29
Quality33
FCF yld1.2%
Earn yld-18%
EV/EBITDA·
ROE-3.2%
Gross mgn56%
Net mgn-74%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 April 2026
关于 바이오노트
BioNote 是一家专注于健康和制药领域的公司，在XKRX市场上市。它专注于诊断和生物产品的开发。